Madrigal Pharmaceuticals Inc. (MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, is on the verge of a crucial event this week.
Non-alcoholic steatohepatitis, or NASH, a more advanced form of non-alcoholic fatty liver disease, is a leading cause of liver related mortality. People with NASH have an increased risk of heart attack, stroke and death. There are no FDA-approved treatments for the disease, yet.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.